2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenAsked about the significance of Circio having over 20 collaborations, plus the collaboration with big pharma: It is a strong sign of validation of the technology, but in biotech companies like Circio, the number of collaborations must be interpreted based on the type of agreements involved. [1] (https://www.circio.com/en/our-partnering-approach/), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece) When a small biotech company has over 20 partners across several fields, it usually means they possess a pure platform technology (like Circio's circVec for circular RNA). Instead of just developing one specific medicine, they have a tool that many other companies want to test in their own projects. [1] (https://www.finansavisen.no/tdn/2026/03/26/06549600/circio-inngar-samarbeid-om-in-vivo-celleterapi), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece), [3] (https://www.circio.com/en/our-partnering-approach/) Here is an assessment of why this is strong, as well as what you need to be aware of as an investor or observer:👍 Why it is strong (The Benefits) External validation: That over 20 academic environments and industry players want to spend time and resources on the technology shows that the concept is taken seriously at a global level. [1] (https://www.circio.com/en/our-partnering-approach/) The Big Pharma deal changes the game: That the project within the central nervous system (CNS) is fully financed by an unnamed "Top 5" pharma giant is the strongest sign of quality. Large pharmaceutical companies conduct extremely thorough technical investigations (due diligence) before signing. [1] (https://www.circio.com/en/circio-presents-strong-rd-financing-and-business-development-progress-in-first-half-year-report/), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece) Many tickets in the lottery: Since the platform is being tested on everything from heart diseases to cancer (cell and gene therapy), the risk is spread. The company is not dependent on only a single clinical trial succeeding. [1] (https://www.circio.com/en/our-pipeline/), [2] (https://www.circio.com/en/circio-enters-fully-funded-feasibility-study-with-major-global-pharmaceutical-corporation/) ⚠️ What to be aware of (The Risk) To assess whether 22 partners are a goldmine or just "noise", one must distinguish between the maturity of the agreements:Type of collaboration What it means for Circio Commercial value now Academic / Early researchTesting at universities (e.g., Karolinska Institutet). Builds necessary data and publications Low (Often costs money rather than earning money). Feasibility studies / Evaluation Other companies (like Full Circles or Acuitas) test whether the technologies fit together. Medium (Often covered by the partner, but rarely provides large sums of cash immediately). Commercial License Agreement A partner buys the rights to use the technology in a specific product. High (Provides upfront payments, milestone payments, and royalties). Summary For Circio, this is very positive because it shows that they are positioning themselves as an early global leader in the delivery of circular RNA. The fact that the project with the pharma giant is proceeding as planned gives the company great credibility. [1] (https://www.circio.com/en/), [2] (https://www.circio.com/en/our-partnering-approach/), [3] (https://www.circio.com/en/circio-presents-strong-rd-financing-and-business-development-progress-in-first-half-year-report/) Nevertheless, one must remember that many of these 22 collaborations are at an early research stage. The real significant value for shareholders is only unlocked when one of these agreements is converted from a "research and evaluation agreement" to an exclusive, large-scale license agreement with billion-potential.
·5 t sittenA little bird told me about a 20-50% increase just Monday, maybe it closes lower than that though.
·6 t sittenBased on technical analysis and market dynamics for Circio Holding (CRNA), it is brewing that cirocio can not only double in the short term, but also tenfold. Short term means 3-6 months. They have a strong financial position with a monopoly on their medical technology. Folketrygdfondet is taking increasing positions and so are a number of large investors. When it comes to the technicals, momentum and RSI are indicative of a strong positive indication with an RSI (Relative Strength Index) over 70, which signals high buying interest and increasing market pressure. Resistance levels: The share price is testing technical resistance zones. A potential breakout through these levels will trigger a strong buy signal. Regarding algorithm patterns and volumm, increasing trading volume combined with positive biotechnological updates and algorithmic buy orders indicates that the stock is experiencing an upward trend channel. We are talking 140-150 kroner in one year, if not more. Do your own assessments and dd. This is not a buy recommendation.
·7 t sitten · MuokattuAmong larger triggers going forward is a possible license agreement with big pharma. Normal time for such a program in CNS is about 1 year, so in November I think there will be enough data for license agreement negotiations to commence. How long it takes can be uncertain. It may also depend on the results. Great data, then I think it will go quickly. I would guess such a deal could come no later than early 2027, but I don't rule out earlier. The very good CNS data published in H1 strengthen the possibilities. Now there is a lot of data in the heart program, and a program with disease data has also been done. Very important and good data came in H1. AaviGen will probably also come during the autumn, so one cannot rule out a partner agreement there too in a special indication even if an internal program is being run. There are many diseases to choose from. It could come faster than we think. Eye is also a possible partner scenario. It would be nice to get someone with cash to fund projects in larger animals. And then there's everything else - Chinese people work fast and GeneAssist is therefore an unpredictable project. CAR-T is the main project at ESGCT in October, so something is happening behind the scenes there. I think it would be strange if a large venture specialist investor doesn't come forward for this case. There is a market for such players in the phase Circio is in now. Then we are talking about large amounts for a smaller ownership stake at a premium price significantly above the stock price. Autumn 2026 could be an intense time for Norwegian biotech and many happy investors.
Thanks for a nice summary here Reset. You bu have a lot constructive to contribute and appreciate your posts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenAsked about the significance of Circio having over 20 collaborations, plus the collaboration with big pharma: It is a strong sign of validation of the technology, but in biotech companies like Circio, the number of collaborations must be interpreted based on the type of agreements involved. [1] (https://www.circio.com/en/our-partnering-approach/), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece) When a small biotech company has over 20 partners across several fields, it usually means they possess a pure platform technology (like Circio's circVec for circular RNA). Instead of just developing one specific medicine, they have a tool that many other companies want to test in their own projects. [1] (https://www.finansavisen.no/tdn/2026/03/26/06549600/circio-inngar-samarbeid-om-in-vivo-celleterapi), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece), [3] (https://www.circio.com/en/our-partnering-approach/) Here is an assessment of why this is strong, as well as what you need to be aware of as an investor or observer:👍 Why it is strong (The Benefits) External validation: That over 20 academic environments and industry players want to spend time and resources on the technology shows that the concept is taken seriously at a global level. [1] (https://www.circio.com/en/our-partnering-approach/) The Big Pharma deal changes the game: That the project within the central nervous system (CNS) is fully financed by an unnamed "Top 5" pharma giant is the strongest sign of quality. Large pharmaceutical companies conduct extremely thorough technical investigations (due diligence) before signing. [1] (https://www.circio.com/en/circio-presents-strong-rd-financing-and-business-development-progress-in-first-half-year-report/), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece) Many tickets in the lottery: Since the platform is being tested on everything from heart diseases to cancer (cell and gene therapy), the risk is spread. The company is not dependent on only a single clinical trial succeeding. [1] (https://www.circio.com/en/our-pipeline/), [2] (https://www.circio.com/en/circio-enters-fully-funded-feasibility-study-with-major-global-pharmaceutical-corporation/) ⚠️ What to be aware of (The Risk) To assess whether 22 partners are a goldmine or just "noise", one must distinguish between the maturity of the agreements:Type of collaboration What it means for Circio Commercial value now Academic / Early researchTesting at universities (e.g., Karolinska Institutet). Builds necessary data and publications Low (Often costs money rather than earning money). Feasibility studies / Evaluation Other companies (like Full Circles or Acuitas) test whether the technologies fit together. Medium (Often covered by the partner, but rarely provides large sums of cash immediately). Commercial License Agreement A partner buys the rights to use the technology in a specific product. High (Provides upfront payments, milestone payments, and royalties). Summary For Circio, this is very positive because it shows that they are positioning themselves as an early global leader in the delivery of circular RNA. The fact that the project with the pharma giant is proceeding as planned gives the company great credibility. [1] (https://www.circio.com/en/), [2] (https://www.circio.com/en/our-partnering-approach/), [3] (https://www.circio.com/en/circio-presents-strong-rd-financing-and-business-development-progress-in-first-half-year-report/) Nevertheless, one must remember that many of these 22 collaborations are at an early research stage. The real significant value for shareholders is only unlocked when one of these agreements is converted from a "research and evaluation agreement" to an exclusive, large-scale license agreement with billion-potential.
- ·5 t sittenA little bird told me about a 20-50% increase just Monday, maybe it closes lower than that though.
- ·6 t sittenBased on technical analysis and market dynamics for Circio Holding (CRNA), it is brewing that cirocio can not only double in the short term, but also tenfold. Short term means 3-6 months. They have a strong financial position with a monopoly on their medical technology. Folketrygdfondet is taking increasing positions and so are a number of large investors. When it comes to the technicals, momentum and RSI are indicative of a strong positive indication with an RSI (Relative Strength Index) over 70, which signals high buying interest and increasing market pressure. Resistance levels: The share price is testing technical resistance zones. A potential breakout through these levels will trigger a strong buy signal. Regarding algorithm patterns and volumm, increasing trading volume combined with positive biotechnological updates and algorithmic buy orders indicates that the stock is experiencing an upward trend channel. We are talking 140-150 kroner in one year, if not more. Do your own assessments and dd. This is not a buy recommendation.
- ·7 t sitten · MuokattuAmong larger triggers going forward is a possible license agreement with big pharma. Normal time for such a program in CNS is about 1 year, so in November I think there will be enough data for license agreement negotiations to commence. How long it takes can be uncertain. It may also depend on the results. Great data, then I think it will go quickly. I would guess such a deal could come no later than early 2027, but I don't rule out earlier. The very good CNS data published in H1 strengthen the possibilities. Now there is a lot of data in the heart program, and a program with disease data has also been done. Very important and good data came in H1. AaviGen will probably also come during the autumn, so one cannot rule out a partner agreement there too in a special indication even if an internal program is being run. There are many diseases to choose from. It could come faster than we think. Eye is also a possible partner scenario. It would be nice to get someone with cash to fund projects in larger animals. And then there's everything else - Chinese people work fast and GeneAssist is therefore an unpredictable project. CAR-T is the main project at ESGCT in October, so something is happening behind the scenes there. I think it would be strange if a large venture specialist investor doesn't come forward for this case. There is a market for such players in the phase Circio is in now. Then we are talking about large amounts for a smaller ownership stake at a premium price significantly above the stock price. Autumn 2026 could be an intense time for Norwegian biotech and many happy investors.Thanks for a nice summary here Reset. You bu have a lot constructive to contribute and appreciate your posts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
6 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenAsked about the significance of Circio having over 20 collaborations, plus the collaboration with big pharma: It is a strong sign of validation of the technology, but in biotech companies like Circio, the number of collaborations must be interpreted based on the type of agreements involved. [1] (https://www.circio.com/en/our-partnering-approach/), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece) When a small biotech company has over 20 partners across several fields, it usually means they possess a pure platform technology (like Circio's circVec for circular RNA). Instead of just developing one specific medicine, they have a tool that many other companies want to test in their own projects. [1] (https://www.finansavisen.no/tdn/2026/03/26/06549600/circio-inngar-samarbeid-om-in-vivo-celleterapi), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece), [3] (https://www.circio.com/en/our-partnering-approach/) Here is an assessment of why this is strong, as well as what you need to be aware of as an investor or observer:👍 Why it is strong (The Benefits) External validation: That over 20 academic environments and industry players want to spend time and resources on the technology shows that the concept is taken seriously at a global level. [1] (https://www.circio.com/en/our-partnering-approach/) The Big Pharma deal changes the game: That the project within the central nervous system (CNS) is fully financed by an unnamed "Top 5" pharma giant is the strongest sign of quality. Large pharmaceutical companies conduct extremely thorough technical investigations (due diligence) before signing. [1] (https://www.circio.com/en/circio-presents-strong-rd-financing-and-business-development-progress-in-first-half-year-report/), [2] (https://medwatch.no/nyheter/legemidler_biotek/article18751582.ece) Many tickets in the lottery: Since the platform is being tested on everything from heart diseases to cancer (cell and gene therapy), the risk is spread. The company is not dependent on only a single clinical trial succeeding. [1] (https://www.circio.com/en/our-pipeline/), [2] (https://www.circio.com/en/circio-enters-fully-funded-feasibility-study-with-major-global-pharmaceutical-corporation/) ⚠️ What to be aware of (The Risk) To assess whether 22 partners are a goldmine or just "noise", one must distinguish between the maturity of the agreements:Type of collaboration What it means for Circio Commercial value now Academic / Early researchTesting at universities (e.g., Karolinska Institutet). Builds necessary data and publications Low (Often costs money rather than earning money). Feasibility studies / Evaluation Other companies (like Full Circles or Acuitas) test whether the technologies fit together. Medium (Often covered by the partner, but rarely provides large sums of cash immediately). Commercial License Agreement A partner buys the rights to use the technology in a specific product. High (Provides upfront payments, milestone payments, and royalties). Summary For Circio, this is very positive because it shows that they are positioning themselves as an early global leader in the delivery of circular RNA. The fact that the project with the pharma giant is proceeding as planned gives the company great credibility. [1] (https://www.circio.com/en/), [2] (https://www.circio.com/en/our-partnering-approach/), [3] (https://www.circio.com/en/circio-presents-strong-rd-financing-and-business-development-progress-in-first-half-year-report/) Nevertheless, one must remember that many of these 22 collaborations are at an early research stage. The real significant value for shareholders is only unlocked when one of these agreements is converted from a "research and evaluation agreement" to an exclusive, large-scale license agreement with billion-potential.
- ·5 t sittenA little bird told me about a 20-50% increase just Monday, maybe it closes lower than that though.
- ·6 t sittenBased on technical analysis and market dynamics for Circio Holding (CRNA), it is brewing that cirocio can not only double in the short term, but also tenfold. Short term means 3-6 months. They have a strong financial position with a monopoly on their medical technology. Folketrygdfondet is taking increasing positions and so are a number of large investors. When it comes to the technicals, momentum and RSI are indicative of a strong positive indication with an RSI (Relative Strength Index) over 70, which signals high buying interest and increasing market pressure. Resistance levels: The share price is testing technical resistance zones. A potential breakout through these levels will trigger a strong buy signal. Regarding algorithm patterns and volumm, increasing trading volume combined with positive biotechnological updates and algorithmic buy orders indicates that the stock is experiencing an upward trend channel. We are talking 140-150 kroner in one year, if not more. Do your own assessments and dd. This is not a buy recommendation.
- ·7 t sitten · MuokattuAmong larger triggers going forward is a possible license agreement with big pharma. Normal time for such a program in CNS is about 1 year, so in November I think there will be enough data for license agreement negotiations to commence. How long it takes can be uncertain. It may also depend on the results. Great data, then I think it will go quickly. I would guess such a deal could come no later than early 2027, but I don't rule out earlier. The very good CNS data published in H1 strengthen the possibilities. Now there is a lot of data in the heart program, and a program with disease data has also been done. Very important and good data came in H1. AaviGen will probably also come during the autumn, so one cannot rule out a partner agreement there too in a special indication even if an internal program is being run. There are many diseases to choose from. It could come faster than we think. Eye is also a possible partner scenario. It would be nice to get someone with cash to fund projects in larger animals. And then there's everything else - Chinese people work fast and GeneAssist is therefore an unpredictable project. CAR-T is the main project at ESGCT in October, so something is happening behind the scenes there. I think it would be strange if a large venture specialist investor doesn't come forward for this case. There is a market for such players in the phase Circio is in now. Then we are talking about large amounts for a smaller ownership stake at a premium price significantly above the stock price. Autumn 2026 could be an intense time for Norwegian biotech and many happy investors.Thanks for a nice summary here Reset. You bu have a lot constructive to contribute and appreciate your posts.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt